Source Fact: Financial Supervisory Service Electronic Disclosure System (DART) / 2024-02-28
Disclosure Type: Submission of Audit Report
💡 3-Second Summary
Samsung Biologics has submitted its audited financial statements for fiscal year 2023, obtaining an “Unmodified” opinion for both consolidated and separate financials from Samil PricewaterhouseCoopers. Under these financial statements, consolidated revenue reached approximately KRW 3.69 trillion and operating profit stood at KRW 1.11 trillion.
📊 1. [Summary of Core Disclosure Content and Major Figures]
- External Auditor: Samil PricewaterhouseCoopers
- Audit Opinion: “Unmodified” for both consolidated and separate financial statements.
- Noted as “Not Applicable” for material uncertainties related to going concern and any material weaknesses in internal control over financial reporting.
- No cases of embezzlement or breach of trust were reported (“No”).
- Major Consolidated Financial Figures for FY2023:
- Revenue: KRW 3,694,588,767,068 (Approx. KRW 3.69T)
- Operating Profit: KRW 1,113,680,009,715 (Approx. KRW 1.11T)
- Net Profit: KRW 857,691,298,384 (Approx. KRW 857.7B)
- Total Assets: KRW 16,046,197,209,196 (Approx. KRW 16.05T) / Total Liabilities: KRW 6,215,704,796,851 (Approx. KRW 6.22T) / Total Equity: KRW 9,830,492,412,345 (Approx. KRW 9.83T)
- Major Separate Financial Figures for FY2023:
- Revenue: KRW 2,938,755,680,729 (Approx. KRW 2.94T) / Operating Profit: KRW 1,204,187,993,041 (Approx. KRW 1.20T) / Net Profit: KRW 945,920,325,918 (Approx. KRW 945.9B)
- Other Details: The number of consolidated subsidiaries increased by one, from 13 in the previous fiscal year to 14. The financial data contained within this audit report is subject to change pending final approval at the annual general meeting of shareholders.
📈 2. [Expert Perspective: What This Disclosure Means for Investors]
- Impact on Fundamental Changes: By officially securing an unmodified opinion from Samil PwC, the baseline financial indicators have successfully passed the formal auditor review process. The presented metrics outline a solid commercial posture with consolidated revenue of KRW 3.69T and operating profit of KRW 1.11T, confirming that revenue tracks ahead of operating profit. Furthermore, total consolidated equity expanded from KRW 8.98T in the prior year to KRW 9.83T, pointing to a potential positive impact regarding baseline capital stability.
- Risks and Red Flags for Investors: As explicitly cautioned within the filing, these audited figures are not yet fully ratified by the general assembly of shareholders, meaning that adjustments could potentially occur during the upcoming ratification process. Additionally, since the regulatory disclosure does not outline the explicit operational causes behind the annual revenue expansion, investors should avoid speculative structural assumptions.
📝 Editor’s Comment (by K-STOCK Editor)
Ahead of the annual general meeting season, the official submission of the audited financial statements with a clean stamp from a major accounting firm fulfills a vital regulatory checkpoint for institutional market participants. This verification provides an independent layer of oversight regarding the company’s historical baseline, tracking its previously disclosed metrics—including a KRW 3.6T top-line and a milestone KRW 1.1T operating profit. However, as stated in the filing, these figures are subject to potential modifications during the final shareholder ratification process. Market analysts will look to follow the steady corporate governance timeline leading into the final shareholder ratification.
📢 Disclaimer and Source Information
Source: This content has been structured and newly written based on official submission data from the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
